Kenta Kambara

611 citations

35 papers · 448 indexed · h-index 13

Co-authors: Ryuji Hayashi Kazuyuki Tobe Seisuke Okazawa Minehiko Inomata Shoko Matsui Toshiro Miwa Shingo Imanishi Kensuke Suzuki
Topics: Lung Cancer Treatments and Mutations (13 papers)Lung Cancer Research Studies (11 papers)Cancer Immunotherapy and Biomarkers (10 papers)
Cited by: Geriatrics and Gerontology Oncology Pulmonary and Respiratory Medicine
Journals: PLoS ONE Scientific Reports Journal of Allergy and Clinical Immunology
Partner nations: Japan United States

In The Last Decade

Kenta Kambara

32 papers receiving 442 citations

Peers

Countries citing papers authored by Kenta Kambara

Since Specialization

Citations

This map shows the geographic impact of Kenta Kambara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenta Kambara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenta Kambara more than expected).

Fields of papers citing papers by Kenta Kambara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenta Kambara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenta Kambara. The network helps show where Kenta Kambara may publish in the future.

Co-authorship network of co-authors of Kenta Kambara

This figure shows the co-authorship network connecting the top 25 collaborators of Kenta Kambara. A scholar is included among the top collaborators of Kenta Kambara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenta Kambara. Kenta Kambara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer 2023 ·Scientific Reports ·Minehiko Inomata,(unknown),Naoki Takata,(unknown),(unknown),(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	10
2	Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer 2022 ·Cancer Diagnosis & Prognosis ·Minehiko Inomata,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	7
3	Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression 2021 ·Cancer Diagnosis & Prognosis ·Minehiko Inomata,Naoki Takata,(unknown),(unknown),(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	4
4	Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors 2021 ·In Vivo ·(unknown),(unknown),Minehiko Inomata,(unknown),(unknown),Naoki Takata,(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Satoshi Nomura,Kazuyuki Tobe	5
5	Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer 2020 ·Tumori Journal ·(unknown),Naoki Takata,(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Minehiko Inomata	2
6	Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy 2020 ·Diagnostics ·Minehiko Inomata,(unknown),Naoki Takata,(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	13
7	Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor 2019 ·Anticancer Research ·Minehiko Inomata,(unknown),Seisuke Okazawa,Shingo Imanishi,(unknown),Kenta Kambara,(unknown),Hiroaki Tanaka,(unknown),(unknown),Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	26
8	Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy 2018 ·Pathology & Oncology Research ·Minehiko Inomata,(unknown),(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Tomomi Ichikawa,Shingo Imanishi,Tōru Yamada,Toshiro Miwa,Ryuji Hayashi,Kazuyuki Tobe	18
9	Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression 2017 ·Oncology and Therapy ·Minehiko Inomata,Hiroaki Tanaka,(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toru Yamada,Toshiro Miwa,Ryuji Hayashi,Kazuyuki Tobe	1
10	SIRT1 and FOXO1 mRNA expression in PBMC correlates to physical activity in COPD patients 2017 ·International Journal of COPD ·(unknown),Ryuji Hayashi,(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Minehiko Inomata,Toru Yamada,Shoko Matsui,Kazuyuki Tobe	19
11	Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy 2017 ·Oncology Research and Treatment ·(unknown),Kensuke Suzuki,Kenta Kambara,Minehiko Inomata,Seisuke Okazawa,Shinya Kajiura,Toshiro Miwa,(unknown),Tatsuhiko Kashii	4
12	Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer 2016 ·Anticancer Research ·Minehiko Inomata,(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Tōru Yamada,Toshiro Miwa,Ryuji Hayashi,Tatsuhiko Kashii,Shoko Matsui,Kazuyuki Tobe	8
13	Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib 2016 ·Molecular and Clinical Oncology ·Minehiko Inomata,Ryuji Hayashi,Hiroaki Tanaka,(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Tomomi Ichikawa,Tōru Yamada,Toshiro Miwa,Tatsuhiko Kashii,Shoko Matsui,Kazuyuki Tobe	18
14	Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib 2015 ·Molecular and Clinical Oncology ·Minehiko Inomata,Ryuji Hayashi,(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Kensuke Suzuki,Tomomi Ichikawa,Toru Yamada,Toshiro Miwa,Tatsuhiko Kashii,Shoko Matsui,Kazuyuki Tobe,Johji Imura	12
15	Effect of Lung Volume on Airway Luminal Area Assessed by Computed Tomography in Chronic Obstructive Pulmonary Disease 2014 ·PLoS ONE ·Kenta Kambara,Kaoruko Shimizu,Hironi Makita,Masaru Hasegawa,Katsura Nagai,Satoshi Konno,Masaharu Nishimura	17
16	In Vivo Depletion of CD206+ M2 Macrophages Exaggerates Lung Injury in Endotoxemic Mice 2014 ·American Journal Of Pathology ·Kenta Kambara,Wakana Ohashi,Kengo Tomita,Michinori Takashina,Shiho Fujisaka,Ryuji Hayashi,Hisashi Mori,Kazuyuki Tobe,Yuichi Hattori	75
17	Relationship of the urine cortisol level with the performance status of patients with lung cancer: a retrospective study 2014 ·Supportive Care in Cancer ·Kensuke Suzuki,Tomomi Ichikawa,(unknown),(unknown),(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Minehiko Inomata,Tōru Yamada,Toshiro Miwa,Shoko Matsui,Tatsuhiko Kashii,Hirokazu Taniguchi,Ryuji Hayashi,Kazuyuki Tobe	3
18	Usefulness of the Palliative Prognostic Index in patients with lung cancer 2014 ·Medical Oncology ·Minehiko Inomata,Ryuji Hayashi,(unknown),(unknown),Seisuke Okazawa,Kenta Kambara,Tomomi Ichikawa,Kensuke Suzuki,Toru Yamada,Toshiro Miwa,Tatsuhiko Kashii,Shoko Matsui,Kazuyuki Tobe	8
19	Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin‐induced mouse model of asthma 2012 ·Respirology ·Tomomi Ichikawa,Ryuji Hayashi,Kensuke Suzuki,Shingo Imanishi,Kenta Kambara,Seisuke Okazawa,Minehiko Inomata,Tōru Yamada,Yu Yamazaki,(unknown),Toshiro Miwa,Shoko Matsui,Isao Usui,Masaharu Urakaze,Yûji Matsuya,Masakiyo Sasahara,Kazuyuki Tobe	71
20	Visceral adipose tissue level, as estimated by the bioimpedance analysis method, is associated with impaired lung function 2011 ·Journal of Diabetes Investigation ·Minehiko Inomata,Yukio Kawagishi,(unknown),Kenta Kambara,Seisuke Okazawa,Yasuo Fukushima,Shingo Imanishi,Tomomi Ichikawa,Kensuke Suzuki,Toru Yamada,(unknown),Chikaaki Kobashi,Minoru Iwata,(unknown),Hideki Origasa,Ryuji Hayashi,Kazuyuki Tobe	14

About Kenta Kambara

Kenta Kambara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Geriatrics and Gerontology, having authored 35 papers that have together received 448 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (11 papers) and Cancer Immunotherapy and Biomarkers (10 papers). The work is most often cited by research in Geriatrics and Gerontology (62 citations), Oncology (165 citations) and Pulmonary and Respiratory Medicine (160 citations). Kenta Kambara has collaborated with scholars based in Japan and United States. Frequent co-authors include Ryuji Hayashi, Kazuyuki Tobe, Seisuke Okazawa, Minehiko Inomata, Shoko Matsui, Toshiro Miwa, Shingo Imanishi, Kensuke Suzuki, Tatsuhiko Kashii and Tomomi Ichikawa. Their work appears in journals such as PLoS ONE, Scientific Reports and Journal of Allergy and Clinical Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact